Skip to content
Open access

BIOM-14 Patterns, risk factors and management of CD19-directed Chimeric Antigen Receptor T-cell therapy failure in CNS lymphoma

Nov 2026 · Neuro-Oncology · 0 citations

Abstract

CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) demonstrates encouraging activity in CNS lymphoma (CNSL), yet most patients ultimately develop progressive disease (PD). Predictors, radiographic patterns, and optimal salvage strategies after CD19-CAR failure remain poorly defined. We retrospectively characterized clinical and radiographic features of CD19-CAR failure in CNSL treated at Massachusetts General Hospital. PD patterns were classified as local (involving or adjacent to baseline lesions) or distant. CNS progression-free survival from CD19-CAR infusion (CNS-PFS1) and from first subsequent progression (CNS-PFS2) were analyzed. CD19-CAR achieved a 60% overall response rate in 60 patients with active recurrent CNSL, including 45% complete and 15% partial responses. Median CNS-PFS1 was 4 months. Radiographic PD occurred in 36 patients and was local in 23.3%, combined local/distant in 16.7%, and distant in 20%. Progression patterns correlated with initial CD19-CAR response: distant relapse predominantly followed complete response, whereas local PD was associated with primary refractory disease. Lesions with peripheral contrast enhancement (pCE) at CD19-CAR infusion correlated with refractory disease, while leptomeningeal disease (LMD) was associated with recurrence following complete response. On multivariable Cox regression, pCE (hazard ratio [HR] 2.75, 95% confidence interval [CI] 1.08-6.68; p = 0.03) and LMD (HR 2.72, 95% CI 1.20-6.25; p = 0.02) were independently associated with shorter CNS-PFS1. At progression, peripheral CD19+ B-cell aplasia was present in 93% of patients, suggesting systemic CD19-CAR persistence despite CNS progression. Median CNS-PFS2 after CD19-CAR failure was 1 month. Immune checkpoint inhibition and lenalidomide-based combinations including rituximab or tafasitamab demonstrated encouraging salvage activity. This study identifies radiographic risk factors and progression patterns associated with CD19-CAR failure in CNSL. Outcomes after progression remain poor, supporting prospective evaluation of rational salvage immunotherapeutic strategies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.